Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced that following a hearing on September 12, 2008, the U.S. Court of Appeals for the District of Columbia has vacated an April 2008 ruling, which granted Teva 180-day exclusivity for its Risperidone Tablets, AB-rated to Janssen’s Risperdal® Tablets. As a result of this decision, the U.S. Food and Drug Administration is no longer enjoined from approving subsequent Abbreviated New Drug Applications (ANDA).

More: continued here

This entry was posted on Monday, September 22nd, 2008 at 7:09 pm and is filed under Bipolar. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.